nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.04.2015

New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?

verfasst von: Peter J. Kudenchuk

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

This review addresses current treatment strategies for nonvalvular atrial fibrillation (AF) and their potential impact on thromboembolic risk and complications. It updates current classification schemes for the arrhythmia and discusses specific treatment alternatives including rate control, pharmacologic rhythm suppression, catheter ablation, and left atrial appendage obliteration, each in context of thromboembolic risks and stroke prevention.

Rahman F, Kwan GF, Benjamin EJ (2014) Global epidemiology of atrial fibrillation. Nat Rev Cardiol 11:639–654CrossRefPubMed

Lin HJ (1996) Stroke severity in atrial fibrillation. Stroke 27:1760–1764CrossRefPubMed

Dulli DA (2003) Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 22:116–123CrossRef

Kalantarian S, Stern TA, Mansour M, Ruskin JN (2013) Cognitive impairment associated with atrial fibrillation. Ann Intern Med 158:338–346CrossRefPubMed

Kalantarian S, Ay H, Gollub RL, Lee H, Retzepi K, Mansour M, Ruskin JN (2014) Association between atrial fibrillation and silent cerebral infarctions. Ann Intern Med 161:650–658CrossRefPubMed

Camm AJ, Kirhchof P, Lip GH, Schotten U, Savelieva I, Ernst S, VanGelder CV, Al-Attar N, Hindricks G, Prendergast B, Heidburchel H, Alfieri O, Angelini A, Atar D, Colonna P, DeCaterina R, DeSutter J, Goette A, Gorenek B, Heidal M, Hohnloser SH, Kohl P, LeHeuzey JY, Ponikowski P, Rutten FH, Schotten U, Savelieva I (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429CrossRefPubMed

January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014:129. doi:10.1161/CIR.0000000000000041

Olesen JB, Lip GYH, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunso J, TOlstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C (2011) Risk of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation. Thromb Haemost 106:739–749CrossRefPubMed

ACTIVE Investigators (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel with Irbesartan for prevention of Vascular Events (ACTIVEW). Lancet 367:1903–12

10.

Stroke prevention in atrial fibrillation investigators (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 348:633–638CrossRef

11.

Charitos EI, Purerfellner H, GLotzer TV, Ziegler PD (2014) Clinical classification of atrial fibrillation poorly reflect its temporal persistence. J Am Coll Cardiol 63:2840–2848CrossRefPubMed

12.

Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY (2011) Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol 58:2225–2232CrossRefPubMed

13.

Boriani G, Diemberger I, Aizcchi M, Valzania C, Gardini B, Cimaglia P, Margignani C, Biffi M (2014) AF burden is important—fact or fiction? Int J Clin Pract 68:444–452CrossRefPubMed

14.

Charitos EI, Stierle U, Ziegler PD, Baldewig M, Robinson DR, Sievers HH, Hanke T (2012) A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence. Circulation 126:806–814CrossRefPubMed

15.

Purerfellner H, Gillis AM, Holbrook R, Hettrick DA (2004) Accuracy of atrial tachycarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 27:983–992CrossRefPubMed

16.

Sanna T, Diener HC, Passman RS, DiLazzaro V, Bernstein RA, Morillo A, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370:2478–2486CrossRefPubMed

17.

Healey JS, Connolly SJ, Gold MR, Israel CW, VanGelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129CrossRefPubMed

18.

Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, VanGelder IC, Hohnloser SH, Calrson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, Healey JF (2014) Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 129:2094–2099CrossRefPubMed

19.

Daod EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Siegler PD (2011) Temporal relationship of atrial tachyarrythmias, cerebrovascular events and systemic embolic based on stored device data. Heart Rhythm 8:1416–1423CrossRef

20.

Wyse DG, Bersh BJ (2004) Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation 109:3089–3095CrossRefPubMed

21.

Shukla A, Curtis AB (2014) Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. Vasc Health Risk Manag 10:1–12PubMedCentralPubMed

22.

Freeman JV, Reynods K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS (2014) Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN Study. Circ Arrhythm Electrophysiol 20

23.

Hoffmayer KS, Scheinman M (2013) Current role of atrioventricular junction ablation. PACE 36:257–265CrossRefPubMed

24.

Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J (2003) Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation. Am J Cardiol 91:15D–26DCrossRefPubMed

25.

Investigators Affirm (2003) Maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 42:20–29CrossRef

26.

Le Heuzey JY, DeFerrari GM, Radzik D, Santini M, Zhu J, Davy JM (2010) A short-term randomized double-blind parallel group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation. J Cardiovasc Electrophysiol 21:597–605CrossRefPubMed

27.

AFFIRM Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 3471825–3471833

28.

Roy D, Talajic M, Nattel S, Wyse DG, Drian P, Lee KL, Bourassa MG, Arnold MO, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, LeHeuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BH, Stevenson LW, Stevenson WG, Thibault B, Waldo A (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677CrossRefPubMed

29.

Israel CW, Gronefeld G, Ehrlich RJ, Li YG, Hohnloser FH (2004) Long term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. J Am Coll Cardiol 43:47–52CrossRefPubMed

30.

Prystowsky EN (2008) The history of atrial fibrillation. J Cardiovasc Electrophysiol 19:575–582CrossRefPubMed

31.

Calkins H, Brugada J, Packer DL, Cappato R < Chen SA, Crins HJ, Damiano RJ, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natqale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ (2007) HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4:816–861

32.

Wilber DJ, Pappone C, Neuzil P, DaPaola A, Marchlinski F, Natale A, Macle L, Daud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA (2010) Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxismal atrial fibrillation. JAMA 303:333–340CrossRefPubMed

33.

Calkins H, Reynolds M, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I (2009) Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation. Circ Arrhythm Electrophysiol 2:349–361CrossRefPubMed

34.

Ouyang F, Titz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Kokturk B, Konstantinidou M, Netzener A, Fuemkranz A, Kuck KH (2010) Long term results of catheter ablation in paroxysmal atrial fibrillation. Circulation 122:2368–2377CrossRefPubMed

35.

Wokhlu A, Hodge DO, Monahan KH, Asirvatham SJ, Friedman PA, Munger TM, Cha YM, Shen WK, Brady PA, Bluhm CM, Haroldson JM, Hammill SC, Packer DL (2010) Long term outcome of atrial fibrillation ablation. J Cardiovasc Electrophhysiol 21:1071–1078CrossRef

36.

Shah RU, Feeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA (2012) Procedural complications, rehospitalizations and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 59:143–149CrossRefPubMed

37.

Weerasooriya R, Khairy P, Litalein J, Macle L, Hocini M, Sacher F, Lellouche N, Knecht S, Wright M, Nault I, Miyazaki S, Scavee C, Clementy J, Haissaguerre M, Jais P (2011) Catheter ablation for atrial fibrillation. J Am Coll Cardiol 57:160–166CrossRefPubMed

38.

Steven D, Rostock T, Lutomsky B, Klemm H, Servatius H, Drewitz I, Friedrichs K, Ventura R, Meinertz T, Willems S (2008) What is the real atrial fibrillation burden after catheter ablation of atrial fibrillation? A prospective rhythm analysis in pacemaker patients with continuous atrial monitoring. Eur Heart J 29:1037–1042CrossRefPubMed

39.

Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, Mallender C, Anderson JL (2013) MUhlestein BJ, Lappe DL, Day JD. Atrial fibrillation ablation patients have long term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 10:1272–1277CrossRefPubMed

40.

Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossilo A, DiBiase L, Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wanzi OM, Bonso A, Callans DJ, Haissaguerre M, Raviele A, Natale A (2010) The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 55:735–743CrossRefPubMed

41.

Ghanbari H, Baser K, Jongnarangsin K, Chugh A, Nallamothu BK, Gillespie BW, Baser HD, Swangasool A, Crawford T, Latchamsetty R, Good E, Pelosi F, Bogun F, Moradyh F, OralH (2014) Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 11:1503–1511

42.

Blackshear JL, Odell JA (1996) Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61:755–759CrossRefPubMed

43.

Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ (2005) Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 150:288–293CrossRefPubMed

44.

DeBacker O, Arnous S, Ihlkemann N, Vejkstrup N, Jorgensen E, Pehrson S, Krieger TDW, Meier P, Sondergaard L, Franzen OW (2014) Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Open Heart 1:e000020. doi:10.1136/openhyrt-2013-00020 CrossRef

45.

Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D (2013) Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation. Circulation 127:720–729CrossRefPubMed

46.

Reddy VY, Sievert H, Halperin J, Doshi S, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D (2014) Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation. JAMA 312:1988–1998CrossRefPubMed

47.

Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY (2014) Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. J Am Coll Cardiol 64:1–12CrossRefPubMed

48.

Levy JH, Spyropoulos AC, Samama CM, Douketis J (2014) Direct oral anticoagulants: new drugs and new concepts. J Am Coll Cardiol Intv 7:1333–1351CrossRef

49.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Answell J, tar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosilo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheught FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 265:982–992

50.

Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC (1993) Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanisms. Neurology 32:32–36CrossRef

51.

Hart RG, Pearce LA, Agular MI (2007) Metaanalysis: anththrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867CrossRefPubMed

Titel: New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?
verfasst von: Peter J. Kudenchuk
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 3/2015
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-015-1181-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Inferior vena cava filters: current best practices

Managing unusual presentations of venous thromboembolism

Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents

Role of thrombophilia testing: con

Engaging with quality improvement in anticoagulation management